

**eTable 2.** Characteristics of patients based on time of relapse

	Time of relapse		p-value
	Before M12 n = 16	After M12 n = 20	
Age at disease onset (years)	44.5 (29.2 - 49.2)	30.0 (23.5 - 36.2)	0.082
Age at disease onset			0.009
≥ 40 years	9 (56.2%)	3 (15.0%)	
< 40 years	7 (43.8%)	17 (85.0%)	
Time from the first attack to MiTX (months)	9.5 (4.8 - 68.0)	33.5 (6.8 - 65.2)	0.633
Time from the first attack to MiTX			0.332
< 24 months	9 (56.2%)	8 (40.0%)	
≥ 24 months	7 (43.8%)	12 (60.0%)	
Serostatus			0.448
NMOSD-DN	1 (6.2%)	3 (15.0%)	
NMOSD-AQP4+	14 (87.5%)	17 (85.0%)	
MOGAD	1 (6.2%)	0 (0.0%)	
ARR the year before MiTX ≥ 1	10 (62.5%)	10 (50.0%)	0.453
Number of IRP*			0.529
0	0 (0.0%)	1 (5.0%)	
[1-2]	14 (87.5%)	14 (70.0%)	
3	2 (12.5%)	5 (25.0%)	
Sex			>0.999
Female	13 (81.2%)	17 (85.0%)	
Male	3 (18.8%)	3 (15.0%)	
Total relapse count before MiTX			>0.999
1	3 (18.8%)	4 (20.0%)	
2	3 (18.8%)	4 (20.0%)	
≥ 3	10 (62.5%)	12 (60.0%)	
MiTX from the first attack	3 (18.8%)	4 (20.0%)	>0.999
P0 with neuritis optica	6 (37.5%)	6 (30.0%)	0.635
P0 with transverse myelitis	10 (62.5%)	14 (70.0%)	0.635
EDSS at T0 ≥ 6	7 (43.8%)	10 (50.0%)	0.709
Previous immunosuppressant therapy	5 (31.2%)	7 (35.0%)	0.813

Abbreviations: AQP4+, positive anti-aquaporin-4 antibody; ARR, annualized relapse rate; DN, double-seronegative; EDSS, Expanded Disability Status Scale; IRP, identified relapse predictors; M12, the 6<sup>th</sup> injection of mitoxantrone; MiTX, mitoxantrone; MOGAD, myelin oligodendrocyte glycoprotein antibody-associated disease; NMOSD, neuromyelitis optica spectrum disorder; P0, last attack before mitoxantrone; T0, initiation of mitoxantrone.

\*IRP, identified relapse predictors in multivariate analysis: delay between the first attack and MiTX ≥ 24 months, AQP4-IgG seropositivity, and a pretreatment ARR ≥ 1.